Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006 Apr;16(2):137-49
Date
12/27/2005Pubmed ID
16376101DOI
10.1016/j.semcancer.2005.11.007Scopus ID
2-s2.0-31644451518 (requires institutional sign-in at Scopus site) 65 CitationsAbstract
Suppressor/regulatory T cells were first shown to have an impact on cancer progression in experimental tumor models during the 1970s. However, the lack of specific markers hindered mechanistic investigations, and skepticism grew in the scientific community due to variability in cell populations and reported functions. The identification of regulatory CD4(+)CD25(+) T cells has generated a great deal of renewed interest in cells that have immune regulatory properties. This article will provide a brief historical review of suppressor T cells and cancer, experimental and clinical evidence that CD4(+)CD25(+) natural regulatory T cells play a role in cancer progression, and briefly discuss current strategies to inhibit these cells in an effort to enhance cancer immunotherapy.
Author List
Orentas RJ, Kohler ME, Johnson BDAuthor
Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
CD4 AntigensHumans
Immune Tolerance
Neoplasms
Receptors, Interleukin-2
T-Lymphocytes, Regulatory
